Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Biotransformation Study of [14C]LXI-15028 in Healthy Chinese Males
NCT05883306Phase 1Completed
- Sponsor
- Shandong Luoxin Pharmaceutical
- Start
- Jun 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tegoprazan in erosive esophagitis (EE), duodenal ulcer and gastroesophageal reflux disease (GERD), sponsored by Shandong Luoxin Pharmaceutical. Primary endpoints: Mass balance at 11 days, Metabolite Profiling at 11 days and 12 more. Started Jun 2022; status: completed.
02
Drugs
tegoprazan
03
Conditions
erosive esophagitis (EE)duodenal ulcergastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05883306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05883306.